

E-Filed 2/18/11

1 MCDERMOTT WILL & EMERY LLP
 WILLIAM G. GAEDE III (136184)
 2 wgaede@mwe.com
 275 Middlefield Road, Suite 100
 3 Menlo Park, CA 94025-4004
 Telephone: (650) 815-7400
 4 Facsimile: (650) 815-7401

5 MCDERMOTT WILL & EMERY LLP
 JOSEPH R. ROBINSON (*Pro Hac Vice*)
 jrobinson@mwe.com
 6 HEATHER MOREHOUSE ETTINGER (*Pro Hac Vice*)
 hettinger@mwe.com
 7 340 Madison Avenue
 New York, NY 10173
 8 Telephone: (212) 547-5509

9 Attorneys for *Plaintiffs*

10 KNOBBE MARTENS OLSON & BEAR LLP
 WILLIAM R. ZIMMERMAN (195859)
 bzimmerman@kmob.com
 11 SHEILA N. SWAROOP (203476)
 sswaroop@kmob.com
 12 BEN KATZENELLENBOGEN (208527)
 bkattenellenbogen@kmob.com
 13 2040 Main Street, 14th Floor
 Irvine, CA 92614-3641
 14 Telephone: (949) 760-0404
 Facsimile: (949) 760-9502

15 Attorney for *Defendant Impax Laboratories, Inc.*

16 THE BANCHERO LAW FIRM LLP
 E. JEFFREY BANCHERO (93077)
 17 ejb@bancherolaw.com
 SCOTT R. RABER (194924)
 18 sraber@bancherolaw.com
 Four Embarcadero Center, 17th Floor
 19 San Francisco, California 94111
 Telephone: (415) 398-7000
 20 Facsimile: (415) 616-7000

21 SUTHERLAND ASBILL & BRENNAN LLP
 JOHN L. NORTH (*Pro Hac Vice*)
 john.north@sutherland.com
 22 JEFFREY J. TONEY (*Pro Hac Vice*)
 jeffrey.toney@sutherland.com
 23 LAURA FAHEY FRITTS (*Pro Hac Vice*)
 laura.fritts@sutherland.com
 24 JONATHAN D. OLINGER (*Pro Hac Vice*)
 jonathan.olinger@sutherland.com
 25 999 Peachtree Street NE
 Atlanta, GA 30309-3996
 26 Telephone: (404) 853-8000

27 Attorneys for *Defendants Watson Pharmaceuticals, Inc.,*
Watson Laboratories, Inc.–Florida, Watson Pharma,
 28 *Inc. and Anda, Inc.*

1 UNITED STATES DISTRICT COURT
2 NORTHERN DISTRICT OF CALIFORNIA
3 SAN FRANCISCO DIVISION

4 SHIRE LLC, SUPERNUS
5 PHARMACEUTICALS, INC., AMY F.T.
6 ARNSTEN, PH.D., PASKO RAKIC,
7 M.D., and ROBERT D. HUNT, M.D.,

8 Plaintiff,

9 v.

10 IMPAX LABORATORIES, INC.,
11 WATSON PHARMACEUTICALS, INC.,
12 WATSON LABORATORIES, INC.–
13 FLORIDA, WATSON PHARMA, INC.,
14 and ANDA, INC.,

15 Defendant.

CASE NO. 10-CV-05467 RS

**STIPULATION TO CONTINUE CASE
MANAGEMENT CONFERENCE AND
CONTINUE ADR DEADLINES; AND
[PROPOSED] ORDER**

Honorable Richard Seeborg

16 WHEREAS, the Case Management Conference is presently scheduled for 10:00 a.m. on
17 March 10, 2011;

18 WHEREAS, Counsel for parties have conferred and concluded that scheduling conflicts
19 exist which prevents one or more counsel from attending the Case Management Conference on
20 the date presently set;

21 WHEREAS, Counsel for parties have agreed that April 14, 2011, is a date on which all
22 counsel would be available to attend the Case Management Conference;

23 IT IS HEREBY STIPULATED AND REQUESTED, by and between the parties hereto,
24 through their respective counsel, as follows:

25 1. The Case Management Conference presently set for March 10, 2011, be continued
26 to April 14, 2011 at 10:00 a.m. in Courtroom 3 of this Court;

27 2. The last day to meet and confer regarding the initial disclosures, early settlement,
28 ADR process selection and discovery plan pursuant to Fed. R. Civ. P. 26(f) and ADR L.R. 3-5
shall be March 24, 2010.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

3. The last day to file the ADR Certification signed by Parties and Counsel pursuant to Civil L.R. 16-8(b) and ADR L.R. 3-5(b) shall be March 24, 2010.

4. The last day to file either a stipulation to an ADR process or a noted of need for an ADR phone conference pursuant to Civil L.R. 16-8(c) and ADR L.R. 3-5(b) and (c) shall be March 24, 2010; and,

5. The Joint Case Management Conference Statement shall be due April 7, 2011;
SO STIPULATED this 18th day of February 2011.

MCDERMOTT WILL & EMERY LLP

By: /s/ William G. Gaede, III
William G. Gaede, III
Attorneys for *Plaintiffs*

KNOBBE MARTENS OLSON & BEAR LLP

By: /s/ Ben Katzenellenbogen
Ben Katzenellenbogen
Attorneys for *Defendant Impax Laboratories, Inc.*

SUTHERLAND ASBILL & BRENNAN LLP

By: /s/ Laura Fahey Fritts
Laura Fahey Fritts
Attorneys for *Defendant Watson Pharmaceuticals, Inc., Watson Laboratories, Inc.-Florida, and Watson Pharma, Inc.*

